NCT06028386 is a NA clinical trial of AC5® Advanced Wound System in Non-healing Wound, sponsored by Arch Therapeutics.

Who is sponsoring NCT06028386?

NCT06028386 is sponsored by Arch Therapeutics.

What drugs are being tested in NCT06028386?

Interventions in NCT06028386: AC5® Advanced Wound System, Fibracol Plus Collagen Dressing.

What condition does NCT06028386 study?

NCT06028386 studies Non-healing Wound, Diabetic Foot Ulcer.

Is NCT06028386 still recruiting?

NCT06028386 is currently status unknown. Last updated 11 September 2023.

Last reviewed 2023-09-11 · How we verify

NCT06028386

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Use of AC5® Advanced Wound System in the Treatment of Diabetic Foot Ulcers

Status unknown NA Last updated 11 September 2023

What this trial tests

NA trial testing AC5® Advanced Wound System in Non-healing Wound in 60 participants. Status unknown.

Timeline

15 August 2023

Primary endpoint
30 April 2024

30 August 2024

Quick facts

Lead sponsor	Arch Therapeutics
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	15 August 2023
Primary completion	30 April 2024
Estimated completion	30 August 2024
Sites	2 locations across United States

Drugs / interventions tested

AC5® Advanced Wound System
Fibracol Plus Collagen Dressing

Conditions studied

Non-healing Wound — all drugs for Non-healing Wound →
Diabetic Foot Ulcer — all drugs for Diabetic Foot Ulcer →

Sponsor

Arch Therapeutics

Who can join

18 and older, any sex, with Non-healing Wound or Diabetic Foot Ulcer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this clinical evaluation is to collect and compare outcomes data from patients with UT 1A diabetic foot ulcers treated with 510K FDA cleared, commercially available self-assembling peptide, AC5®Advanced Wound System, as compared to an advanced standard of care. Patient outcomes will be compared at the end of the study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Advances in nucleic acid delivery strategies for diabetic wound therapy.
Sarthi S, Bhardwaj H, Kumar Jangde R. · · 2024 · cited 4× · PMID 39286540 · DOI 10.1016/j.jcte.2024.100366

Verify or expand the search:

Other recruiting trials for Non-healing Wound

Currently open trials in the same condition.

NCT06327113 — Antibiotic Tumescent For Chronic Wounds · Phase 2 · recruiting
NCT05739149 — A Study to Evaluate Microvessel Ultrasound Imaging of Wound Healing in Patients With Chronic Ulcers · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06028386 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Arch Therapeutics
Last refreshed: 11 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06028386.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing